Axi‐cel, tisa‐cel, liso‐cel, and brexu‐cel are genetically modified anti‐CD19 autologous CAR‐T‐cells that are designed to target CD19 in B‐cell malignancies, and all four have showed significant activity in poor risk R/R NHL as herein discussed. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.